Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.

MLA

Yonezawa, Hajime, et al. “Three-Year Follow-up Analysis of Phase 1/2 Study on Tirabrutinib in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma.” Neuro-Oncology Advances, vol. 6, no. 1, Apr. 2024, p. vdae037. EBSCOhost, https://doi.org/10.1093/noajnl/vdae037.

APA

Yonezawa, H., Narita, Y., Nagane, M., Mishima, K., Terui, Y., Arakawa, Y., Asai, K., Fukuhara, N., Sugiyama, K., Shinojima, N., Aoi, A., & Nishikawa, R. (2024). Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma. Neuro-Oncology Advances, 6(1), vdae037. https://doi.org/10.1093/noajnl/vdae037

Chicago

Yonezawa, Hajime, Yoshitaka Narita, Motoo Nagane, Kazuhiko Mishima, Yasuhito Terui, Yoshiki Arakawa, Katsunori Asai, et al. 2024. “Three-Year Follow-up Analysis of Phase 1/2 Study on Tirabrutinib in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma.” Neuro-Oncology Advances 6 (1): vdae037. doi:10.1093/noajnl/vdae037.